Kubra Nur Toplutas

Kubra Nur Toplutas

Auto-generated profile, based on publicly available information

Kubra Nur Toplutas

Department of Nucleer Medicine, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
BOBuket Caliskaner Ozturk
Buket Caliskaner Ozturk
EAErsan Atahan
Ersan Atahan
AGAysegul Gencer
Aysegul Gencer
DHDeniz Ongel Harbiyeli
Deniz Ongel Harbiyeli
EKEmine Karabul
Emine Karabul
SBSermin Borekci
Sermin Borekci


5 October 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Seçkin BilgiçSeçkin Bilgiç
Seçkin Bilgiç
BAB. Akovali
B. Akovali
KTK. N. Toplutas
K. N. Toplutas
Merve OkuyanMerve Okuyan
Merve Okuyan
VGVildan Gursoy
Vildan Gursoy
EAEray Alper
Eray Alper
Standardized interpretation of [18F]FDG PET/CT in multiple myeloma remains challenging because reproducibility varies across visual parameters. The Italian Myeloma criteria for PET Use (IMPeTUs) provide a structured framework, but evidence on intra-observer and inter-observer agreement remains limited, particularly across institutions. We prospectively registered patients with histopathologically confirmed multiple myeloma undergoing [18F]FDG PET/CT between March and September 2025. Fifty patients were included according to a prespecified target sample size. After anonymization, three independent nuclear medicine physicians from different institutions evaluated all examinations twice over 10 weeks using a blinded repeated-reader design with software-randomized weekly case allocation and presentation order. Intra-observer agreement was assessed using Cohen’s kappa, inter-observer agreement using Krippendorff’s alpha and pairwise kappa, and differences between reading rounds using permutation-based methods. An exploratory whole-patient binary metabolic status analysis using a Deauville score 4 threshold was also performed. Inter-observer agreement was highest for Lytic Lesion Group (α = 0.683 and 0.784) and Hottest Bone Focal Lesion Deauville score (α = 0.657 and 0.641). Bone Marrow Deauville score showed α values of 0.560 and 0.626, whereas Focal Lesion Group yielded 0.538 and 0.491. Fracture and Extramedullary Disease Presence showed lower agreement (α = 0.280 and 0.235; α = 0.412 and 0.262, respectively). Intra-observer agreement was highest for Hottest Bone Focal Lesion Deauville score (κ = 0.846–0.891), Lytic Lesion Group (κ = 0.759–0.905), and Focal Lesion Group (κ = 0.679–0.855). For exploratory patient-level binary metabolic status, inter-observer agreement was moderate to good (α = 0.611 and 0.542), while intra-observer agreement was good to excellent (κ = 0.626–0.822). No parameter showed a statistically significant change between reading rounds. IMPeTUs supports structured [18F]FDG PET/CT interpretation in multiple myeloma, but reproducibility differs across components, underscoring the need for clearer operational definitions and targeted training for less reproducible parameters.